What Is Multiple Myeloma And How Does Multiple Myeloma Affect the Body?
Multiple myeloma is a cancer derived from plasma cells, which are part of the white blood cells that reside in the bone marrow and are producers of antibodies. In multiple myeloma, these plasma cells proliferate and interfere with the normal cells to work properly, thus leading to a decreased ability to produce normal blood cells. This results in anemia (reduced red blood cell count), a higher frequency of infections, and, lastly, slow blood clotting. Moreover, these malignant cells produce a monoclonal protein that may form a deposit that leads to damage to the organs, especially the kidneys. It also promotes the uncontrolled proliferation of tumor cells.
It stimulates bone remodeling to increase bone resorption, initiating painful osseous lesions and hypercalcemia (increased blood calcium level) with complications such as renal failure (a medical condition where the kidneys lose their ability to filter waste and excess fluids from the blood) and neurological manifestation due to spinal compression. Multiple myeloma impacts several organs of the human body, pointing to the fact that early diagnosis and treatment of the disease is a crucial step towards minimizing the impact of the disease on the patient’s body.
Which Laboratory Tests Are Crucial for Diagnosing Multiple Myeloma?
To accurately diagnose multiple myeloma, several specialized laboratory tests are essential, each playing a pivotal role in confirming the presence and extent of the disease:
-
Complete Blood Count (CBC): This test is a simple test that counts the number of red blood cells, white blood cells, and platelets in the individual’s blood sample. Some symptoms of multiple myeloma include a low count of red blood cells, which is referred to as anemia. Patients may have different WBCs (white blood cells) and platelets because the malignant cells replace the normal cells in the bone marrow.
-
Serum Protein Electrophoresis (SPEP): SPEP is significant in the presence of pathologic proteins or M proteins in the blood flow because myelomatous cells synthesize these proteins in large amounts. They are essential in diagnosing multiple myeloma and are done by testing for M proteins in clinical samples.
-
Serum Free Light Chains (FLC) Test: This particular test is important when the free light chains in the body system fluids need to be measured. An increased kappa or lambda ratio of light chains in the blood can distinguish multiple myeloma. In most cases, this is used to diagnose the severity of the disease and estimate the effectiveness of the applied therapeutic interventions.
-
Urine Protein Electrophoresis (UPEP): Bence Jones proteins showing that the latter are free light chains sufficiently small to filter through in the urine; UPEP test. This test is important as these proteins are toxic to the kidneys and are found in about sixty percent of the multiple myeloma patients.
-
Immunofixation Electrophoresis (IFE): IFE is the procedure of separating various types of proteins and light chains in the blood. The urine better reveals the picture of the proteins produced by the myeloma cells.
-
Beta-2 Microglobulin (β2M) Test: We already know that the increased value of β2M indicates poor prognosis and increased size of myeloma clone, which can be detected by serum protein electrophoresis. It is usually used for the simulation of the disease or to predict the result and the recommended treatment concerning the result.
What Role Do Imaging Techniques Play in Multiple Myeloma Diagnosis?
Other complementary procedures help in the staging of multiple myeloma to know how advanced the cancer is within the body. Here are the key imaging modalities used:
-
X-rays: Multiple myeloma employs plain films and conventional skeletal surveys as the initial imaging modality. They are used to show bone lesions or osteolytic changes that appear as punched-out lesions, typical in the vertebral column, skull, and long bones. However, they are not liable for the early manifestation of the disease, and X-rays are favorable for diffuse changes in bones.
-
Magnetic Resonance Imaging (MRI): MRI is also very sensitive in detecting persons with infiltration of bone marrow that is not amenable to being identified as affected through bone pain or deformation as viewed on plain X-ray. It can create images of the bone marrow and all the other soft tissues as well, which helps in staging and predicting the patient's survival by seeing how diseases are spread in the bone marrow.
-
Computed Tomography (CT) Scans: CT scans are more accurate than X-ray imaging, provide information within a shorter time, and detect small bone lesions. They are particularly relevant where MRI is contraindicated or the patient has hardware cannot be MRI’d.
-
Positron Emission Tomography (PET) Scans: The PET, when integrated with CT scan PET/CT, remains useful in detecting metabolically active myeloma cells in the body. PET uses radioactive sugar, which is injected into the bloodstream, and the tumor cells will light as they consume more sugar than the normal cells. PET/CT can help in staging the disease, determining the activity of the disease and response towards the treatment, and detecting the early signs of disease relapse.
-
Whole Body Low-Dose CT (WBLDCT): It creates images of the bone and may define the lesions with a higher contrast and accuracy as compared to traditional or non contrast X-rays and does not expose the organ to radiation, as in the case with CT scans.
Why Is a Bone Marrow Biopsy Essential for Confirming Multiple Myeloma?
The bone marrow biopsy is the only procedure that can describe the amount and caliber of the myeloma cells in the bone marrow environment. However, this procedure also makes it possible in several cases to demonstrate that monoclonal plasma cells synthesize M-protein, which puts into question other tests, such as blood and urine tests, as well as to carry out tests to assess certain cytogenetic changes in the chromosomes. These indications are critical in interpreting the prognosis of the disease, individual patient management care, and the severity of the illness. The same can be said with the hip biopsy; a bone marrow biopsy sets a base at which the profile and evolution of the disease and its treatment response can be compared. This broad data acquisition is important for the long-lasting reconstitution of the disease, the present modulation of treatment, and the therapeutic changes to the degree of response for the best management strategy in patients with multiple myeloma.
Conclusion
Hence, it is crucial to diagnose multiple myeloma adequately to help identify the most appropriate treatment regime. Currently, there is hope in enhancing diagnostic instruments and efficient knowledge about the genetic makeup of the disease; it becomes easier to stage and treat the ailments for the individual. Future research will undoubtedly build on our current diagnostic processes and thus help patients with this complicated condition.
